openPR Logo
Press release

Mucormycosis Market 2019 Analysis - Research Covers Top 10 Players as Abbott Laboratories, Biocon Limited, Cadila Pharmaceuticals Limited, Novartis AG, F. Hoffman La Roche

01-17-2019 01:55 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Market Research Future

/ PR Agency: Market Research Future
Mucormycosis Market

Mucormycosis Market

Market Research Future has added a report titled “Mucormycosis Market Research Report- Global Forecast till 2023” to its offering.

Market Scenario:

Mucormycosis (zygomycosis) is a serious but rare fungal infection caused by a group of molds called mucormycetes. Moreover, inhaling fungal spores from the air can affect the lungs and sinuses, the fungus also invades the skin through wounds such as cut, scrape, burn, or other type of skin trauma. There are approximately 1.5 million different species of fungi on the earth, however, only around 300 are responsible for causing diseases and infections in humans. Fungal infection may affect anyone, but they are most common in people with weakened immune systems and can occur in nearly any part of the body. Risk factors for developing mucormycosis include uncontrolled diabetes, cancer, organ transplant, neutropenia, skin trauma such as cuts, scrapes, punctures, or burns.

Get Premium Copy @ https://www.marketresearchfuture.com/sample_request/5440

These infections need to be treated with prescribed antifungal medication, usually amphotericin B, posaconazole or isavuconazole. Amphotericin B, posaconazole, and isavuconazole are medications given intravenously. Furthermore, posaconazole and isavuconazole can also be administered orally. Often, mucormycosis requires surgery to remove the infected tissue.

The prognosis of mucormycosis is usually poor. It depends on various factors such as the overall health of the patient and ability to respond to treatments, the speed of diagnosis, and treatment provided. For instance, the mortality rate with rhinocerebral and GI mucormycosis is about 85% while the mortality rate for patients with other types of mucormycosis is about 50%. Patients who survive this infection often end up having disabilities such as blindness, limb loss, organ dysfunctions among others.

The market growth is mainly driven by increasing prevalence of fungal infections, availability of wide range of products, and rising incident of immunological diseases. Moreover, increasing awareness about fungal infection and increasing government support for research & development have fuelled the market growth. However, side effects of the treatment and presence of misbranded and spurious drugs may slow the growth of the market. There are a number of medicines available in the market for the treatment of fungal infections such as oral and intravenous medicines, creams, sprays, shampoos, solutions, and pessaries.

Rising incidence of immunological diseases and availability of a wide range of products has driven the growth of the global mucormycosis market. Furthermore, rising geriatric population, increasing government support, and increasing healthcare expenditure have fueled the growth of the market. However, side effects of the drugs and presence of misbranded drugs may hinder the growth of the market.

The global market for mucormycosis is expected to grow at a CAGR of approximately 7.3% during the forecast period, 2017-2023.

Key Players:

The Global Mucormycosis Market key players are Abbott Laboratories (U.S.), Biocon Limited (India), Cadila Pharmaceuticals Limited (India), Novartis AG (Switerzland), F. Hoffman La Roche (Switerzland), Merck Sharp and Dohme (U.S.), Mylan Labs (U.S.), Bristol Myers Squibb (U.S.), Bayer AG (Germany), Lonza Group (Switerzland), Sanofi (France), Johnson & Johnson (U.S.), Pfizer Inc. (U.S.), Gilead Sciences (U.S.), and others

Segmentation:

The mucormycosis is segmented on the basis of species, diagnosis, treatment, and end-users.

On the basis of the species, the market is segmented into Rhizopus, Rhizomucor, Cunninghamella, Apophysomyces, Saksenaea, Lichtheimia (formerly Absidia), and Mucor, and others

On the basis of the diagnosis, the market is segmented into Computed Tomography (CT), Magnetic resonance imaging (MRI), tissue biopsy, and others.

On the basis of the treatment, the market is segmented into surgery, antifungal drugs, amphotericin B therapy, and others. The antifungal drugs is further categorized into posaconazole, isavuconazole, voriconazole, fluconazole, and flucytosine, and others.

On the basis of the end-user, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.

Browse Full Reports @ https://www.marketresearchfuture.com/reports/mucormycosis-market-5440

Regional Analysis:

The Global Mucormycosis Market consists of countries namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas dominate the global mucormycosis market owing to a well-developed healthcare sector and huge patient population for mucormycosis. Many antifungal drugs have lost their patients during the last few years such as Terbinafine products like Lamisil lost their patient in 2017. As there is limited oral preparation in the market, development and licensing of new drugs in the market is the huge opportunity for the development of the market during the forecasted period.

Europe is the second largest market for the global mucormycosis owing to the advancements in the technology of the surgical devices along with the rising occurrence of fungal infections among the patients. The European government introduced incentives to help simplify the improvement of anti-infective drugs and dropping the risk and cost of manufacturers. Some other factors driving the market include the growing percentage of diabetes mellitus population mainly in the developed countries of Europe. The average diabetes prevalence rate in Europe is 8.6% of the adult population.

Asia Pacific is the fastest growing region for antifungal treatment due to increasing prevalence of HIV, and huge untapped growth opportunities for the development of the market. Every year, approximately 7.1% of the Korean population receives treatment for fungal diseases. Therefore, further research is needed to understand and monitor the prevalence of mycoses to establish management policies to reduce the burden of fungal diseases.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Mucormycosis Market 2019 Analysis - Research Covers Top 10 Players as Abbott Laboratories, Biocon Limited, Cadila Pharmaceuticals Limited, Novartis AG, F. Hoffman La Roche here

News-ID: 1508634 • Views: 677

More Releases from Market Research Future

Dermal Fillers Market Business Insights & Deep Analysis to 2025 by World’s Top …
Market Scope The global dermal filler market can reach a valuation of USD 6,899.16 million by 2025. It is predicted to expand at a CAGR of 13.2% over the forecast period. Dermal fillers or wrinkle fillers are solutions injected into the skin. Its effects can last from six months to two years. Efforts are being made to prolong its effects and revolutionize anti-aging. The global dermal filler market report by Market Research
Field Programmable Gate Array Market 2021 Size, Share, Industry Analysis, Emergi …
Field Programmable Gate Array Market by technology (EEPROM, Antifuse, SRAM, Flash, and others (EPROM and PROM), by Application (data processing, consumer electronics, industrial, military & aerospace, automotive, telecom, and others), and by Type (high-end, mid-end, and low-end FPGA) - Global Opportunity Analysis and Industry Forecast, 2017-2023 According to a recent report published by Allied Market Research, titled, Field Programmable Gate Array Market by Technology, Application, and Type: Global Opportunity Analysis and
Semiconductor IC Tester Market Growth Factor, Demand, Size, Share, Trends, Growt …
The Semiconductor IC Tester Market research report includes Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the Semiconductor IC Tester market growth. Semiconductor IC Tester is
Tilt Sensor Market Share, COVID-19 Pandemic Impact, Comprehensive Analysis, Oppo …
Global Tilt Sensor Market Highlights: The global Tilt Sensor Market is growing rapidly over 7.42% of CAGR and is expected to reach at USD 257.64 million by the end of forecast period. The global tilt sensor market has been witnessing a steady growth over the last few years on account of rapid growth of automobile and transportation market, high implementation of sensors in the constructions machines and rising demand for tilt

All 5 Releases


More Releases for Mucor

Microbial Coagulants Market : Financial Status over Forecast Period 2018 – 202 …
Microbial Coagulants Market: Market Outlook Microbial coagulants are derived typically from the Rhizomucor miehei, are fermentation-produced chymosin from either fungi or yeast. They are an organic, non-GMO, non-animal product and has Kosher and halal certification by recognized certifying authorities in various regions and countries. The microbial coagulants are produced by controlled fermentation of Rhizomucor miehei or pusillus, used in the food industry predominantly for cheese production. Microbial coagulants produce optimal taste profiles,
Zygomycosis Treatments Market can be segmented on the basis of fungi type, treat …
Zygomycosis is an acute or chronic life-threatening infection caused by several fungal agents belonging to the phylum Zygomycota. The instances of zygomycosis have been gradually increasing over the past decade. Zygomycetes are a relatively primitive class of fungi found in soil and decaying vegetation. Most infections are caused due to the fungi belonging to various genera such as Mucor (M. circinelloides), Rhizopus (R. arrhizus), Rhizomucor (R. pusillus), Absidia (A. corymbifera)
Mucormycosis Market 2018 | Top Most Vendors | Gilead Sciences, Abbott Laboratori …
Crystal Market Research has announced the addition of the "Mucormycosis Market Growth, Trends and Forecast, 2018-2025" report to their offering. Mucormycosis Market by Species (Rhizopus, Mucor, Cunninghamella, Lichtheimia, Rhizomucor, Apophysomyces, Saksenaea and Other Species), Diagnosis Method (Tissue Biopsy, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) and Other Diagnosis Method), Treatment (Surgery, Antifungal Drugs, Amphotericin B Therapy Other Treatments) and End User (Medical Institutes, Hospitals & Clinics, Research Organization and Other End
Mucormycosis Market Set to Surge Significantly During 2026
Mucormycosis is a rapidly progressive and life-threatening invasive fungal disease with high morbidity and mortality rates despite treatment. It primarily affects immunocompromised patients such as those with organ and bone marrow transplantation and hematological malignancy and patients with diabetes, cancer, neutropenia, and skin trauma. In rare cases it also affects immunocompetent patients. Mucormycosis is caused by a group of molds called mucormycetes. Inhaling the spores of the molds can affect
Mucormycosis Weltmarkt wird zu wachsen an einer CAGR von ca. 7,3 % zur Zeit der …
Marktforschung-Zukunft hat einen halbgaren Forschung Bericht auf dem globalen Mucormycosis-Markt, Weltmarkt für Mucormycosis voraussichtlich wachsen an einer CAGR von ca. 7,3 % im Prognosezeitraum, 2017-2023 Vor auch bekannt als Mucormycosis ist eine seltene Infektion verursacht durch Organismen, die zu einer Gruppe von Pilzen genannt Mucoromycotinagehören. Diese Pilze sind in der Regel im Boden gefunden und sind verbunden mit verwesenden organischen Stoffen, wie Blätter, Komposthaufen oder morsches Holz. Die Behandlungen für Mucormycosis
United States Posaconazole Market- Global Strategic Business Report 2017 With Pr …
The United States Posaconazole Market Research Report 2017 renders deep perception of the key regional market status of the Posaconazole Industry on a United States level that primarily aims the core regions which comprises of continents like Europe, North America, and Asia and the key countries such as United States, Germany, China and Japan. Request For Sample Of United States Posaconazole Market Research Report @ https://www.qyresearchgroups.com/request-sample/470526 The report on “United States Posaconazole